Literature DB >> 17619531

The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients.

Jean-Yves Wilputte1, Pierre Goffette, Francis Zech, Armando Godoy-Gepert, André Geubel.   

Abstract

OBJECTIVES: Hepatic hydrothorax is a rare but challenging complication of cirrhosis. The Transjugular Intrahepatic Portosystemic Shunt (TIPS) appears as one of the most successful approach of therapy.
METHODS: To assess long-term efficacy and safety, we reviewed 28 patients (Child B/C: 43/57%) who underwent TIPS placement for refractory hepatic hydrothorax in our institution between 1992 and 2001.
RESULTS: The 30-days mortality was 14%, reaching 25% at 90 days. The one-year survival without liver transplantation was 41.2%. Reduction in the volume of pleural effusion and improvement in clinical symptoms was observed in 68% while a complete radiological and echographic disappearance of hydrothorax was documented in 57%. Statistical analysis showed that poor liver function was predictive of mortality and non-response. Of the different liver function parameters and in this small series, the Child-Pugh score was more discriminating than the recently described Mayo risk score.
CONCLUSION: This study shows that TIPS is effective in the treatment of hepatic hydrothorax for selected patients. Poor liver function is a strong predictive of bad outcome.

Entities:  

Mesh:

Year:  2007        PMID: 17619531

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  23 in total

1.  Outcomes of patients with chest tube insertion for hepatic hydrothorax.

Authors:  Eric S Orman; Anna S F Lok
Journal:  Hepatol Int       Date:  2009-08-11       Impact factor: 6.047

2.  A fascinating presentation of hepatic hydrothorax.

Authors:  Vinaya Gaduputi; Hassan Tariq; Kalyan Kanneganti
Journal:  World J Hepatol       Date:  2013-10-27

3.  Paradigms in the management of hepatic hydrothorax: past, present, and future.

Authors:  Sachin Kumar; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2012-09-25       Impact factor: 6.047

Review 4.  Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage.

Authors:  Romaric Loffroy; Louis Estivalet; Violaine Cherblanc; Sylvain Favelier; Pierre Pottecher; Samia Hamza; Anne Minello; Patrick Hillon; Pierre Thouant; Pierre-Henri Lefevre; Denis Krausé; Jean-Pierre Cercueil
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

Review 5.  Transjugular intrahepatic portosystemic shunt.

Authors:  Kavish R Patidar; Malcolm Sydnor; Arun J Sanyal
Journal:  Clin Liver Dis       Date:  2014-08-27       Impact factor: 6.126

6.  Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis.

Authors:  Harjit K Bhogal; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2011-06-21       Impact factor: 11.382

7.  Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis.

Authors:  Ivo C Ditah; Badr F Al Bawardy; Behnam Saberi; Chobufo Ditah; Patrick S Kamath
Journal:  World J Hepatol       Date:  2015-07-08

Review 8.  An Algorithm for Management After Transjugular Intrahepatic Portosystemic Shunt Placement According to Clinical Manifestations.

Authors:  Seung Kwon Kim; Bryan G Belikoff; Carlos J Guevara; Seong Jin Park
Journal:  Dig Dis Sci       Date:  2017-01-05       Impact factor: 3.199

Review 9.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 10.  [Pulmonary complications of liver cirrhosis: hepatopulmonary syndrome, portopulmonary hypertension and hepatic hydrothorax].

Authors:  M Halank; C P Strassburg; M M Hoeper
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.